Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-19-010124
Filing Date
2019-08-06
Accepted
2019-08-06 16:06:03
Documents
9
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 6-K auph-0630196xk.htm 6-K 17947
2 EXHIBIT 99.2 exhibit991-20190630interim.htm EX-99.2 688236
3 EXHIBIT 99.3 exhibit992-20190630mda.htm EX-99.3 378488
4 EXHIBIT 99.4 exhibit993-20190630certifi.htm EX-99.4 15994
5 EXHIBIT 99.5 exhibit994-20190630certifi.htm EX-99.5 15740
6 aurinialogoweb700pxa06.jpg GRAPHIC 77311
7 auroralogoa01.jpg GRAPHIC 12814
8 consolidatedfinancialstate01.jpg GRAPHIC 233177
9 consolidatedfinancialstate02.jpg GRAPHIC 233177
  Complete submission text file 0001628280-19-010124.txt   1873162
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36421 | Film No.: 191002081
SIC: 2834 Pharmaceutical Preparations